In vitro Heparan Sulfate Modulates the Immune Responses of Normal and Tumor-Bearing Mice

REFERENCES

• Adam J. K., Odhav B., Bhoola K. D. Immune responses in cancer. Pharmacol. Ther. 2003; 99(1)113–132
   PubMed Web of Science ®Google Scholar
• Batra R. K., Lin Y., Sharma S., Dohadwala M., Luo J., Pold M., Dubinett S. M. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism. Cancer Res. 2003; 63(3)642–646
   PubMedGoogle Scholar
• Crowley M., Inaba K., Witmer-Pack M., Steinman R. M. The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. Cell Immunol. 1989; 118(1)108–125
   PubMedGoogle Scholar
• Fields R. C., Shimizu K., Mule J. J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 1998; 95(16)9482–9487
   PubMed Web of Science ®Google Scholar
• Giuntoli R. L., II, Lu J., Kobayashi H., Kennedy R., Celis E. Direct costimulation of tumor-reactive CTL by helper T-cells potentiate their proliferation, survival, and effector function. Clin. Cancer Res. 2002; 8(3)922–931
   PubMedGoogle Scholar
• Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 1997; 3(5)558–561
   PubMed Web of Science ®Google Scholar
• Inaba K. Isolation of dendritic cells. Current Protocols in Immunology, J.E. Coligan. John Wiley & Sons, New York 1998; 3.7.1
   Google Scholar
• Ishida K., Wierzba M. K., Teruya T., Simizu S., Osada H. Novel heparan sulfate mimetic compounds as antitumor agents. Chem. Biol. 2004; 11(3)367–377
   PubMedGoogle Scholar
• Jalal S., Alai M. S., Khan K. A., Jan V. M., Rather H. A., Iqbal K., Tramboo N. A., Lone N. A., Dar M. A., Hayat A., Abbas S. M. Silent myocardial ischemia and cardiac autonomic neuropathy in diabetics. J. Assoc. Physicians India 1999; 47(8)767–479
   PubMedGoogle Scholar
• Kruisbeek A. M. Isolation and fractionation of mononuclear cell populations. Current Protocols in Immunology, J. E. Coligan. John Wiley & Sons, New York 1998; 3.1
   Google Scholar
• Lathers D. M., Achille N. J., Young M. R. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum. Immunol. 2003; 64(12)1160–1166
   PubMed Web of Science ®Google Scholar
• Lathers D. M., Young M. R. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine 2004; 25(5)220–228
   PubMed Web of Science ®Google Scholar
• Lipscombe R. J., Nakhoul A. M., Sanderson C. J., Coombe D. R. Interleukin-5 binds to heparin/heparan sulfate. A model for an interaction with extracellular matrix. J. Leukoc. Biol. 1998; 63(3)342–350
   PubMedGoogle Scholar
• Maeda H., Kuwahara H., Ichimura Y., Ohtsuki M., Kurakata S., Shiraishi A. TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J. Immunol. 1995; 155(10)4926–4932
   PubMed Web of Science ®Google Scholar
• Maeda H., Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J. Immunol. 1996; 156(1)73–78
   PubMed Web of Science ®Google Scholar
• Mocellin S., Rossi C. R., Nitti D. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp. Cell Res. 2004; 299(2)267–278
   PubMed Web of Science ®Google Scholar
• Pellegrini P., Contasta I., Berghella A. M., Del Beato T., Casciani C. U., Adorno D. The Th1 and Th2 cytokine network in healthy subjects: suggestions for experimental studies to create prognostic and diagnostic indices for biotherapeutic treatments. Cancer Biother. Radiopharm. 2000; 15(3)67–79
   Google Scholar
• Rashid R. M., Achille N. J., Lee J. M., Lathers D. M., Young M. R. Decreased T-cell proliferation and skewed immune responses in LLC-bearing mice. JEPTO 2005; 24(3)175–192
   Google Scholar
• Rashid R. M., Jawed F., Lee J. M., Young M. R. In vivo Heparan Sulfate effects on normal and LLC-bearing mice. Immunopharmacol. Immunotoxicol. 2006; 28(1)
   PubMedGoogle Scholar
• Shibagaki N., Udey M. C. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J. Immunol. 2002; 168(5)2393–2401
   PubMedGoogle Scholar
• Tiefenthaler M., Marksteiner R., Neyer S., Koch F., Hofer S., Schuler G., Nussenzweig M., Schneider R., Heufler C. M1204, a novel 2′,5′ oligoadenylate synthetase with a ubiquitin-like extension, is induced during maturation of murine dendritic cells. J. Immunol. 1999; 163(2)760–765
   PubMedGoogle Scholar
• von Bernstorff W., Voss M., Freichel S., Schmid A., Vogel I., Johnk C., Henne-Bruns D., Kremer B., Kalthoff H. Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 2001; 7(3 Suppl)925s–932s
   PubMed Web of Science ®Google Scholar
• Walzer M., Lorens S., Hejna M., Fareed J., Hanin I., Cornelli U., Lee J. M. Low molecular weight glycosaminoglycan blockade of beta-amyloid induced neuropathology. Eur. J. Pharmacol. 2002; 445(3)211–220
   PubMedGoogle Scholar
• Wang H., Cheng F., Cuenca A., Horna P., Zheng Z., Bhalla K., Sotomayor E. M. Imatinib mesylate (STI-571) enhances antigen presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2004; 105(3)1135–1143
   PubMedGoogle Scholar
• Wong R. J., Chan M. K., Yu Z., Kim T. H., Bhargava A., Stiles B. M., Horsburgh B. C., Shah J. P., Ghossein R. A., Singh B., Fong Y. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin. Cancer Res. 2004; 10(1 Pt 1)251–259
   PubMed Web of Science ®Google Scholar
• Woo E. Y., Chu C. S., Goletz T. J., Schlienger K., Yeh H., Coukos G., Rubin S. C., Kaiser L. R., June C. H. Regulatory CD4+CD25+ T-cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001; 61(12)4766–4772
   PubMed Web of Science ®Google Scholar
• Woo E. Y., Yeh H., Chu C. S., Schlienger K., Carroll R. G., Riley J. L., Kaiser L. R., June C. H. Cutting edge: Regulatory T-cells from lung cancer patients directly inhibit autologous T-cell proliferation. J. Immunol. 2002; 168(9)4272–4276
   PubMed Web of Science ®Google Scholar
• Wrenshall L. Role of the microenvironment in immune responses to transplantation. Springer Semin. Immunopathol. 2003; 25(2)199–213
   PubMedGoogle Scholar
• Wrenshall L. E., Carlson A., Cerra F. B., Platt J. L. Modulation of cytolytic T-cell responses by heparan sulfate. Transplantation 1994; 57(7)1087–1094
   PubMedGoogle Scholar
• Wrenshall L. E., Cerra F. B., Carlson A., Bach F. H., Platt J. L. Regulation of murine splenocyte responses by heparan sulfate. J Immunol 1991; 147(2)455–459
   PubMedGoogle Scholar
• Wrenshall L. E., Cerra F. B., Geller R. L., Carlson A., Bach F. H., Platt J. L. Heparan sulfate augments the splenocyte response to mitogenic stimuli. Transplant Proc. 1991; 23(1 Pt 1)325
   PubMedGoogle Scholar
• Wrenshall L. E., Cerra F. B., Rubinstein P., Platt J. L. Regulation by heparan sulfate and interleukin 1 alpha of the ontogenic expression of T-cell receptor, CD4, and CD8 in developing thymus. Hum. Immunol. 1993a; 38(3)165–171
   PubMedGoogle Scholar
• Wrenshall L. E., Platt J. L. Regulation of T-cell homeostasis by heparan sulfate-bound IL-2. J. Immunol. 1999; 163(7)3793–3800
   PubMedGoogle Scholar
• Wrenshall L. E., Platt J. L., Stevens E. T., Wight T. N., Miller J. D. Propagation and control of T-cell responses by heparan sulfate-bound IL-2. J. Immunol. 2003; 170(11)5470–5474
   Google Scholar
• Wrenshall L. E., Stevens R. B., Cerra F. B., Platt J. L. Modulation of macrophage and B cell function by glycosaminoglycans. J. Leukoc. Biol. 1999b; 66(3)391–400
   PubMed Web of Science ®Google Scholar
• Yamamoto N., Zou J. P., Li X. F., Takenaka H., Noda S., Fujii T., Ono S., Kobayashi Y., Mukaida N., Matsushima K., et al. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T-cells or macrophages in the tumor-bearing state. J. Immunol. 1995; 154(5)2281–2290
   PubMedGoogle Scholar
• Yoshitomi Y., Nakanishi H., Kusano Y., Munesue S., Oguri K., Tatematsu M., Yamashina I., Okayama M. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett. 2004; 207(2)165–174
   PubMed Web of Science ®Google Scholar
• Young M. R., Kolesiak K., Achille N. J., Meisinger J., Gonzalez E., Liu S. W., Wrone-Smith T., Lathers D. M. Impact of aging on immune modulation by tumor. Cancer Immunol. Immunother. 2001a; 50(6)315–320
   PubMedGoogle Scholar
• Young M. R., Petruzzelli G. J., Kolesiak K., Achille N., Lathers D. M., Gabrilovich D. I. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34+ progenitor cells. Hum. Immunol. 2001b; 62(4)332–341
   PubMedGoogle Scholar
• Zitvogel L., Mayordomo J. I., Tjandrawan T., DeLeo A. B., Clarke M. R., Lotze M. T., Storkus W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T-cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 1996; 183(1)87–97
   PubMed Web of Science ®Google Scholar